These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 30974160)
21. Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib. Karademir B; Sari G; Jannuzzi AT; Musunuri S; Wicher G; Grune T; Mi J; Hacioglu-Bay H; Forsberg-Nilsson K; Bergquist J; Jung T Sci Rep; 2018 Nov; 8(1):16318. PubMed ID: 30397214 [TBL] [Abstract][Full Text] [Related]
22. Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms. Yang L; Zhang S; George SK; Teng R; You X; Xu M; Liu H; Sun X; Amin HM; Shi W Oncotarget; 2015 Jun; 6(17):14953-69. PubMed ID: 25879451 [TBL] [Abstract][Full Text] [Related]
23. Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Dreger H; Westphal K; Weller A; Baumann G; Stangl V; Meiners S; Stangl K Cardiovasc Res; 2009 Jul; 83(2):354-61. PubMed ID: 19351736 [TBL] [Abstract][Full Text] [Related]
24. Oxidized SOD1 alters proteasome activities in vitro and in the cortex of SOD1 overexpressing mice. Le Pecheur M; Bourdon E; Paly E; Farout L; Friguet B; London J FEBS Lett; 2005 Jul; 579(17):3613-8. PubMed ID: 15961078 [TBL] [Abstract][Full Text] [Related]
25. Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance. Wu YX; Yang JH; Saitsu H Oncotarget; 2016 Nov; 7(47):77622-77634. PubMed ID: 27769058 [TBL] [Abstract][Full Text] [Related]
27. Targeting Bortezomib to Bone Increases Its Bone Anabolic Activity and Reduces Systemic Adverse Effects in Mice. Wang H; Zhang H; Srinivasan V; Tao J; Sun W; Lin X; Wu T; Boyce BF; Ebetino FH; Boeckman RK; Xing L J Bone Miner Res; 2020 Feb; 35(2):343-356. PubMed ID: 31610066 [TBL] [Abstract][Full Text] [Related]
28. The Proteasome Inhibitor Bortezomib Induces Apoptosis and Activation in Gel-Filtered Human Platelets. Ghansah H; Debreceni IB; Fejes Z; Nagy B; Kappelmayer J Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445660 [TBL] [Abstract][Full Text] [Related]
29. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma. Arkwright R; Pham TM; Zonder JA; Dou QP Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682 [TBL] [Abstract][Full Text] [Related]
30. Protection of vascular cells from oxidative stress by proteasome inhibition depends on Nrf2. Dreger H; Westphal K; Wilck N; Baumann G; Stangl V; Stangl K; Meiners S Cardiovasc Res; 2010 Jan; 85(2):395-403. PubMed ID: 19679681 [TBL] [Abstract][Full Text] [Related]
31. A drastic superoxide-dependent oxidative stress is prerequisite for the down-regulation of IRP1: Insights from studies on SOD1-deficient mice and macrophages treated with paraquat. Milczarek A; Starzyński RR; Styś A; Jończy A; Staroń R; Grzelak A; Lipiński P PLoS One; 2017; 12(5):e0176800. PubMed ID: 28542246 [TBL] [Abstract][Full Text] [Related]
32. Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma. Ri M Int J Hematol; 2016 Sep; 104(3):273-80. PubMed ID: 27169614 [TBL] [Abstract][Full Text] [Related]
33. Proteasomal inhibition by misfolded mutant superoxide dismutase 1 induces selective motor neuron death in familial amyotrophic lateral sclerosis. Urushitani M; Kurisu J; Tsukita K; Takahashi R J Neurochem; 2002 Dec; 83(5):1030-42. PubMed ID: 12437574 [TBL] [Abstract][Full Text] [Related]
34. Activation of the cardiac proteasome promotes angiotension II-induced hypertrophy by down-regulation of ATRAP. Li N; Wang HX; Han QY; Li WJ; Zhang YL; Du J; Xia YL; Li HH J Mol Cell Cardiol; 2015 Feb; 79():303-14. PubMed ID: 25526681 [TBL] [Abstract][Full Text] [Related]
35. Effects of Cellular Pathway Disturbances on Misfolded Superoxide Dismutase-1 in Fibroblasts Derived from ALS Patients. Keskin I; Forsgren E; Lange DJ; Weber M; Birve A; Synofzik M; Gilthorpe JD; Andersen PM; Marklund SL PLoS One; 2016; 11(2):e0150133. PubMed ID: 26919046 [TBL] [Abstract][Full Text] [Related]
36. Bortezomib-Encapsulated Dual Responsive Copolymeric Nanoparticles for Gallbladder Cancer Targeted Therapy. Chen M; Juengpanich S; Li S; Topatana W; Lu Z; Zheng Q; Cao J; Hu J; Chan E; Hou L; Chen J; Chen F; Liu Y; Jiansirisomboon S; Gu Z; Tongpeng S; Cai X Adv Sci (Weinh); 2022 Mar; 9(7):e2103895. PubMed ID: 35068071 [TBL] [Abstract][Full Text] [Related]
37. Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma. Yoshida T; Ri M; Kinoshita S; Narita T; Totani H; Ashour R; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S PLoS One; 2018; 13(5):e0196780. PubMed ID: 29738534 [TBL] [Abstract][Full Text] [Related]
38. Toxic Effects and Possible Mechanisms of Deoxynivalenol Exposure on Sperm and Testicular Damage in BALB/c Mice. Yang JH; Wang JH; Guo WB; Ling AR; Luo AQ; Liu D; Yang XL; Zhao ZH J Agric Food Chem; 2019 Feb; 67(8):2289-2295. PubMed ID: 30707021 [TBL] [Abstract][Full Text] [Related]
39. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells. Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565 [TBL] [Abstract][Full Text] [Related]
40. Bortezomib alleviates experimental pulmonary arterial hypertension. Kim SY; Lee JH; Huh JW; Kim HJ; Park MK; Ro JY; Oh YM; Lee SD; Lee YS Am J Respir Cell Mol Biol; 2012 Nov; 47(5):698-708. PubMed ID: 22842494 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]